IntelliPharmaCeutics – How Is This Nigerian Connected Company Doing In NASDAQ?

IntelliPharmaCeutics Intl Inc was created by Nigerian couple living in Canada.  It a pharma company that operates from Canada. Recently it was listed on the NASDAQ and traded as IPCI. The stock has a value of $3.74 with a yearly low – high of  $2.05 -$ 6.12. Of course, they will push that stock higher in coming months and years. Tekedia profiled this company and couple few weeks ago; they are awesome.

What is IntelliPharmaCeutics Intl Inc?

We are engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. In some circumstances, controlled-release drug delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug.

Our proprietary Hypermatrix™ technology is at the core of our controlled-release drug delivery approach. The flexibility of the Hypermatrix™ technology allows for the intelligent and efficient design of drugs through the precise control of a number of key variables. This allows us to respond to varying drug attributes and patient requirements, producing a desired controlled-release effect in a time and cost-effective manner.

The founders

Isa Odidi, Ph.D., MBA

Chairman, CEO, CSO
In 1998, Dr. Isa Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. From 1995 to 1998, Dr. Odidi held positions, first as Director, then as Vice President of Research of Drug Development and New Technologies, at Biovail Corporation International (now Biovail Corporation), a drug delivery company. Prior to 1995, Dr. Isa Odidi held senior positions in academia and in the pharmaceutical and health care industries. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles, and textbooks. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine in California. Dr. Odidi received his B.Sc. degree in Pharmacy, and his M.Sc. in Pharmaceutical Technology and his Ph.D. in Pharmaceutics from the University of London. Dr. Odidi is also a graduate of the Western Executive Management Program and obtained his MBA from the Rotman School of Business at the University of Toronto.
Amina Odidi , Ph.D.

President, COO, CSO
In 1998, Dr. Amina Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. She has been President, COO, and Co-Chief Scientist since 1998. Dr. Amina Odidi has extensive experience developing and applying proprietary technologies to the development of controlled-release drug products for third-party pharmaceutical companies. She is constantly being blogged about on small but noticeable websites like She has invented or co-invented various proprietary controlled delivery devices for the delivery of pharmaceutical, nutriceutical, biological, agricultural and chemical agents. Previously she has worked for the pharmaceutical and health care industry. She has co-authored 8 articles, papers and textbooks. She received her B.Sc. in Pharmacy, M.S. in Biopharmaceutics, and her Ph.D. in Pharmaceutics from the University of London.

Share this post

Post Comment